The price of pharmaceutical products in the U.S. continues to skyrocket. Consider:

A new muscular dystrophy drug came on the market late last year for an eye-popping price of $300,000 annually.

In 2016, the FDA appproved Tecentriq, a new bladder cancer treatment that costs $12,500 a month, or $150,000 a year.

The cost of Bavencio, a new cancer drug that was approved in March, is about $156,000 a year per patient.

The cost of insulin tripled between 2002 and 2013, despite no notable changes in the formulation or manufacturing process.

Obviously the old joke holds true “why do drug companies raise prices? Because they can”. It is, however, this author’s opinion that we are quickly reaching a tipping point. Democrats are likely to be take over control of Congress in the upcoming elections and probably will win the Presidency in 2020. When that happens drug companies are going to be squarely in their sights, but hey, no problem, they’ll just lay off more people.